Over 5000 COVID-19 patients already analyzed with Fluidda’s new blood vessel volume FRI parameter

We are pleased to announce that CT scans of more than 5000 COVID-19 patients from all corners of the world have been analyzed with Fluidda’s recently developed BVX parameter!

The BVX parameter measures the blood vessel volumes of the pulmonary vascular bed. This easy-to-apply measurement is now being used regularly for better triage and predicting adverse outcomes in patients with COVID-19 disease seeking acute medical care. The COVID-19 pandemic has placed momentous pressure on the healthcare system, and with BVX we enable doctors to make more informed decisions quickly. A BVX analysis only takes 20 minutes, and in an acute setting time is often of the essence.

Recent research using BVX measurements has already resulted in several publications, which you can view here and here.

Categorised in: Miscellaneous / March 10, 2021 10:53 am / Published by Fluidda

Tags: BVX, COVID

Drug delivery and lung deposition using the Aerosphere™ inhaler, a study performed with FRI technology.

Novel FRI parameter analyzing the pulmonary vascular bed accurately predicts outcomes in COVID-19 disease, and can be decisive in choice of therapy.